Compass Therapeutics (CMPX) Enterprise Value (2018 - 2026)
Compass Therapeutics (CMPX) reported Enterprise Value of -$194.7 million for Q1 2026, down 72.85% on a YoY basis from -$717.0 million in Q1 2025, and up 7.06% sequentially from -$209.5 million in Q4 2025.
Compass Therapeutics (CMPX) Enterprise Value (2018 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 9 years of Enterprise Value data on file, last reported at -$194.7 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 72.85% year-over-year to -$194.7 million; the trailing twelve-month figure through Mar 2026 stood at -$194.7 million (down 72.85% YoY), and the FY2025 full-year result was -$209.5 million, down 64.56% from the prior year.
- Enterprise Value improved to -$194.7 million in Q1 2026, from -$209.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$100.9 million in Q2 2025 to a low of -$219.9 million in Q3 2025.
- A 5-year average of -$154.2 million and a median of -$152.5 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value sank 372.78% in 2022 and surged 30.96% in 2025, its largest moves.
- Tracing CMPX's Enterprise Value over 5 years: stood at -$186.6 million in 2022, then increased by 18.28% to -$152.5 million in 2023, then rose by 16.51% to -$127.3 million in 2024, then sank by 64.56% to -$209.5 million in 2025, then increased by 7.06% to -$194.7 million in 2026.
- Business Quant data shows CMPX's Enterprise Value at -$194.7 million in Q1 2026, -$209.5 million in Q4 2025, and -$219.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | -194.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -194.69 Mn |
| Dec 31, 2025 | -209.47 Mn |
| Sep 30, 2025 | -219.90 Mn |
| Jun 30, 2025 | -100.95 Mn |
| Mar 31, 2025 | -112.64 Mn |
| Dec 31, 2024 | -127.29 Mn |
| Sep 30, 2024 | -118.01 Mn |
| Jun 30, 2024 | -146.23 Mn |
| Mar 31, 2024 | -156.58 Mn |
| Dec 31, 2023 | -152.46 Mn |
| Sep 30, 2023 | -163.70 Mn |
| Jun 30, 2023 | -168.75 Mn |
| Mar 31, 2023 | -175.17 Mn |
| Dec 31, 2022 | -186.56 Mn |
| Sep 30, 2022 | -120.60 Mn |
| Jun 30, 2022 | -132.02 Mn |
| Mar 31, 2022 | -136.38 Mn |
| Dec 31, 2021 | -144.51 Mn |
| Sep 30, 2021 | -25.51 Mn |
| Mar 31, 2021 | -39.70 Mn |